CLAIMS

What is claimed is:

1. A compound which is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxymethyl)aminomethane (Formula (IA):



Formula (IA)

2. A compound according to claim 1, wherein the compound is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxymethyl)aminomethane anyhydrate.

3. A compound according to claim 1 or 2, wherein the compound is crystalline.

4. A compound according to any one of claims 1 to 3 wherein the crystalline form of the compound is characterised by an XRPD pattern comprising the following peaks:

Position (± 0.2° 2-theta)	d-spacing ((Å))
10.1	8.7
10.5	8.4
12.2	7.3
13.0	6.8
13.5	6.5
17.3	5.1
17.5	5.1
17.9	5.0
18.3	4.8
19.2	4.6
19.8	4.5
20.2	4.4

20.6	4.3
20.9	4.2
21.7	4.1
22.1	4.0
23.3	3.8
23.9	3.7
24.6	3.6
26.3	3.4
27.1	3.3
27.9	3.2
28.2	3.2
28.6	3.1
29.6	3.0

5. A compound according to any one of claims 1 to 4 wherein the crystalline form of the compound is characterised by an XRPD pattern that is substantially as shown in Figure 2.

6. A compound according to any one of claims 1 to 5 wherein the crystalline form of the compound is characterised by a melting endotherm with an onset melting temperature of 212 ± 2 °C in a DSC thermogram.

7. A compound according to any one of claims 1 to 6 wherein the crystalline form of the compound is characterised by the following absorption peaks in an ATR-IR spectrum of the solid product: 3370, 3041, 2946, 2858, 1680, 1656, 1528, 1266, 1243, 1078, 1068, 1049 ± 1 cm-1.

8. A compound according to any one of claims 1 to 7 wherein the crystalline form of the compound is characterised in that it has an ATR infra red spectrum that is substantially as shown in Figure 6.

9. A combination comprising a) a compound as defined in any one of claims 1 to 8 and b) one or more therapeutically active agents.

10. A combination comprising a) a compound as defined in any one of claims 1 to 8 and b) Niacin or Atorvastatin sodium.

11. A compound as defined in any one of claims 1 to 8 for use in therapy.

12. A compound as defined in any one of claims 1 to 8 for use in the of treatment of mixed dyslipidaemia, diabetic dyslipidaemia or hyperlipoproteinaemia.

13. A compound as defined in any one of claims 1 to 8 for use in the of treatment of Type II diabetes mellitus.

14. A compound as defined in any one of claims 1 to 8 for use in the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease, atherosclerosis, arteriosclerosis, hypertriglyceridaemia, Type II diabetes mellitus, Type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke.

15. The use of a compound as defined in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of mixed dyslipidaemia, diabetic dyslipidaemia or hyperlipoproteinaemia.

16. The use of a compound as defined in one of claims 1 to 8 in the manufacture of a medicament for the treatment of Type II diabetes mellitus.

17. The use of a compound as defined in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease atherosclerosis, arteriosclerosis, hypertriglyceridaemia, Type II diabetes mellitus, Type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke.

18. A method for the treatment of a human subject having a condition where under-activation of HM74A receptor contributes to the condition or where activation of the HM74A receptor will be beneficial, which method comprises administering to said human subject an effective amount of the compound as defined in any one of claims 1 to 8.

19. A method according to claim 18, wherein the human subject has diabetic dyslipidaemia, mixed dyslipidaemia or hyperlipoproteinaemia.

20. A method according to claim 18, wherein the human subject has Type II diabetes mellitus.

21. A pharmaceutical formulation comprising: a) a compound as defined in any one of claims 1 to 8 and b) one or more pharmaceutically acceptable carriers.

22. A method for preparation of a compound as defined in any one of claims 1 to 8, said method comprising a step of mixing a compound of Formula (A)



Formula (A)

with tris(hydroxymethyl)aminomethane.

CLAIMS

What is claimed is:

1. A compound which is crystalline 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxymethyl)aminomethane anhydrate (Formula (IA):



Formula (IA)

2. A compound according to claim 1 wherein the crystalline form of the compound is characterised by an XRPD pattern comprising the following peaks:

Position (± 0.2° 2-theta)	d-spacing ((Å))
10.1	8.7
10.5	8.4
12.2	7.3
13.0	6.8
13.5	6.5
17.3	5.1
17.5	5.1
17.9	5.0
18.3	4.8
19.2	4.6
19.8	4.5
20.2	4.4
20.6	4.3
20.9	4.2
21.7	4.1
22.1	4.0
23.3	3.8

23.9	3.7
24.6	3.6
26.3	3.4
27.1	3.3
27.9	3.2
28.2	3.2
28.6	3.1
29.6	3.0

3. A compound according to any one of claims 1 to 2 wherein the crystalline form of the compound is characterised by an XRPD pattern that is substantially as shown in Figure 2.

4. A compound according to any one of claims 1 to 3 wherein the crystalline form of the compound is characterised by a melting endotherm with an onset melting temperature of 212 ± 2 °C in a DSC thermogram.

5. A compound according to any one of claims 1 to 4 wherein the crystalline form of the compound is characterised by the following absorption peaks in an ATR-IR spectrum of the solid product: 3370, 3041, 2946, 2858, 1680, 1656, 1528, 1266, 1243, 1078, 1068, 1049 ± 1 cm-1.

6. A compound according to any one of claims 1 to 5 wherein the crystalline form of the compound is characterised in that it has an ATR infra red spectrum that is substantially as shown in Figure 6.

7. A combination comprising a) a compound as defined in any one of claims 1 to 6 and b) one or more therapeutically active agents.

8. A compound as defined in any one of claims 1 to 6 for use in therapy.

9. A compound as defined in claim 8 for use in the of treatment of mixed dyslipidaemia, diabetic dyslipidaemia or hyperlipoproteinaemia.

10. A compound as defined in claim 8 for use in the of treatment of Type II diabetes mellitus.

11. A compound as defined in claim 8 for use in the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease, atherosclerosis, arteriosclerosis, hypertriglyceridaemia, Type II diabetes mellitus, Type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke.

12. A compound as defined in claim 8 for use in the treatment of multiple sclerosis.

13. A pharmaceutical formulation comprising: a) a compound as defined in any one of claims 1 to 6 and b) one or more pharmaceutically acceptable carriers.

14. A method for preparation of a compound as defined in any one of claims 1 to 6, said method comprising a step of mixing a compound of Formula (A)



Formula (A)

with tris(hydroxymethyl)aminomethane